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Most of the HIV-1 vaccines under development contain
multiple viral genes or proteins. As a result, many vaccine-
recipients react positive in licensed HIV-1 detection
assays. This will have negative impact on future efficacy
trials of prophylactic HIV vaccines that require early detec-
tion of intercurrent HIV infections. It will also exclude all
vaccinees from blood/plasma donations, and may con-
tribute to other social harms. Therefore, it is important to
design new strategies for vaccine trial participants that will
clearly discriminate between vaccine-induced antibodies
and true HIV-1 infection. We identified new HIV-1
epitopes that: 1) Do not contain important neutralizing
or CTL epitopes, and can be omitted from future HIV vac-
cine candidates, 2) Recognized by antibodies from early
HIV infected individuals, 3) Highly conserved among
HIV-1 clades and subtypes. Using Phage Display libraries
constructed from whole HIV-1 genome, combined with
panning over antibodies from early seroconvertors, we
identified new immunodominant epitopes, in the gp41
intracytoplasmic tail and in p6, which conform to the
above criteria.
These peptides were used for the development of new
HIV-1 EIA. To date the assay specificity and sensitivity are
at >99%. Based on reactivity of several well-characterized
panels of seroconvertors it was demonstrated that these
peptides could detect antibodies within 4 weeks of HIV-1
infection. Testing of diverse serum samples (>2100) from
around the world supports the utilization of our assay in
detecting antibodies from infected individuals with clades
A, B, C, D, E, F, and multiple recombinants. Importantly,
testing of sera from HIV-1 vaccine trials gave mostly nega-
tive reactivity in our assay while scoring positive in one or
more of the currently FDA-licensed HIV-1/2 EIA kits. Fur-
thermore, our assay detected intercurrent HIV infections
among vaccine recipients in 4 different vaccine trials. This
assay could be added to the HIV detection kits used in pro-
phylactic vaccine trials and blood/plasma collection cent-
ers.
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